The rapid, nongenomic effects of estrogen are increasingly recognized as playing an important role in several aspects of estrogen action. Rapid activation of the mitogen-activated protein kinase (MAPK) signaling pathway by estrogen is among the more recently identified of these effects. To explore the role of estrogen receptors (ERs) in mediating these effects, we have transfected ER-negative Rat-2 fibroblasts with complementary DNA clones encoding either human ER␣ or rat ER␤ and examined their ability to couple to activation of MAPK in response to 17␤-estradiol (17␤-E 2 ) and other ligands. For both receptors, addition of E 2 resulted in a rapid phosphorylation of MAPK. Activation of MAPK in ER␣-transfected cells was partially and completely blocked by the antiestrogens tamoxifen and ICI 182,780, respectively. In ER␤-transfected cells, MAPK activation was less sensitive to inhibition by tamoxifen and ICI 182,780. We have also observed that, in this model system, a membraneimpermeable estrogen (BSA-E 2 ) and 17␣-E 2 were both able to activate MAPK in a manner similar to E 2 alone. Here also, ICI 182,780 blocked the ability of BSA-E 2 to activate MAPK through ER␣, but failed to block ER␤-mediated effects. BSA-E 2 treatment, however, failed to activate nuclear estrogen-response-element-mediated gene transcription. These data show that these nuclear ERs are necessary for estrogen's effects at the membrane. This model system will be useful in identifying molecular interactions involved in the rapid effects mediated by the ERs. (Endocrinology 142: 2336 -2342, 2001) 
ABSTRACT
The rapid, nongenomic effects of estrogen are increasingly recognized as playing an important role in several aspects of estrogen action. Rapid activation of the mitogen-activated protein kinase (MAPK) signaling pathway by estrogen is among the more recently identified of these effects. To explore the role of estrogen receptors (ERs) in mediating these effects, we have transfected ER-negative Rat-2 fibroblasts with complementary DNA clones encoding either human ER␣ or rat ER␤ and examined their ability to couple to activation of MAPK in response to 17␤-estradiol (17␤-E 2 ) and other ligands. For both receptors, addition of E 2 resulted in a rapid phosphorylation of MAPK. Activation of MAPK in ER␣-transfected cells was partially and completely blocked by the antiestrogens tamoxifen and ICI 182,780, respectively. In ER␤-transfected cells, MAPK activation was less sensitive to inhibition by tamoxifen and ICI 182,780. We have also observed that, in this model system, a membraneimpermeable estrogen (BSA-E 2 ) and 17␣-E 2 were both able to activate MAPK in a manner similar to E 2 alone. Here also, ICI 182,780 blocked the ability of BSA-E 2 to activate MAPK through ER␣, but failed to block ER␤-mediated effects. BSA-E 2 treatment, however, failed to activate nuclear estrogen-response-element-mediated gene transcription. These data show that these nuclear ERs are necessary for estrogen's effects at the membrane. This model system will be useful in identifying molecular interactions involved in the rapid effects mediated by the ERs. (Endocrinology 142: 2336 -2342, 2001) E STROGEN RECEPTORS (ER␣ and ER␤) are members of the superfamily of nuclear steroid hormone receptors, which are able to regulate the transcriptional activity of target genes by interacting with different DNA response elements. Classically, ERs are thought to bind ligand, dimerize, and activate transcription at estrogen response elements (EREs). It has also been shown that both ERs can interact with fos/jun to form a complex that augments transcription at activator protein-1 (AP-1) sites (1) . In addition to its ability to mediate gene transcription, estrogen also elicits rapid, nontranscriptional effects (2) , including changes in intracellular calcium (3) , increases in cAMP (4, 5) , modulation of neuronal calcium channels (6) and potassium channels (7), phosphorylation of cAMP response element binding protein (CREB) (8, 9) , and activation of mitogen-activated protein kinase (MAPK) (10 -12) . The rapidity of these responses and the ability of membrane-impermeable estrogens to activate MAPK (11) have led to the proposal that these actions may involve a novel, membrane-bound ER (13) . Alternatively, recent evidence has shown that the known ERs may mediate many of these rapid effects. Transient transfection of ER␣ into COS cells results in estrogen-induced interaction of receptor with the nonreceptor tyrosine kinase, src, and activation of MAPK (10) . A recent report (14) has demonstrated that ER␣ or ER␤, transiently transfected into Chinese hamster ovary (CHO) cells, can localize to the membrane and mediate several of the previously reported rapid effects of estradiol (E 2 ), including MAPK activation, increases in cAMP, and phosphatidylinositol hydrolysis.
This laboratory has previously reported that a 24-h pretreatment with E 2 can protect neurons from glutamate toxicity (15) . More recently, we have shown that this protection may involve activation of the MAPK pathway via activation of src (12) . The MAPK pathway is further implicated as a crucial player in estrogen-dependent neuroprotection, by the finding that tyrosine phosphorylation of sos1, grb2, and p21 ras -GTP activating protein all increase within minutes of estrogen exposure. Neuroprotection can be blocked by the addition of the MEK1 inhibitor, PD98059, as well as ICI 182,780, suggesting an ER-dependent mechanism. To further characterize the kinetics and ligand specificity of ER-mediated MAPK activation, we have transfected Rat-2 fibroblasts and selected stable cell lines expressing either ER␣ or ER␤. This model system will be useful in dissecting the molecular mechanisms underlying the rapid actions of estrogen. U/ml), and streptomycin (0.1 mg/ml; Sigma, St. Louis, MO). For estrogen studies, the cells were serum-starved in phenol red-free DMEM supplemented with penicillin and streptomycin, 24 -36 h before treatment. Drugs (17␤-E 2 , 17␣-E 2 , BSA-E 2 , and tamoxifen) were obtained from Sigma. BSA-conjugated E 2 was purified following the protocol described by Stevis et al. (1999) , using a Microcon cartridge with a 3-kDa cut-off (Amicon, Beverly, MA). ICI 182,780 was obtained from Zeneca Pharmaceuticals (Wilmington, DE).
Vector constructs
The complementary DNAs (cDNAs) encoding both human ER␣ (16) and rat ER␤ (17) were subcloned into the R1 site of the expression vector, pcDNA3 (Invitrogen, Carlsbad, CA), which contains the Neo resistance gene for selection in G418.
Generation of stable ER␣ and ER␤ cell lines
Plates (100 mm) of Rat-2 cells (50 -60% confluent) were transfected with 5 g ER␣/pcDNA3 or ER␤/pcDNA3 using standard calcium phosphate procedures described elsewhere (Promega Corp., Madison, WI). After 48 h, cells were split 1:10 into media containing 500 g/ml G418 (Life Technologies, Inc., Gaithersburg, MD). Single G418-resistant colonies were picked after 10 days, and assayed by Western blotting for E 2 -mediated MAPK activation using an antiactive MAPK antibody (Phospho-p44/p42 MAPK; New England Biolabs, Inc., Beverly, MA).
MAPK phosphorylation
A monoclonal antibody that recognizes the dual phosphorylation state of MAPK on Thr202 and Tyr204 (Phospho-p44/42 MAPK; New England Biolabs, Inc.) was used to detect activation of MAPK. Whole-cell lysates were prepared in immunoprecipitation buffer (2.5 mm HEPES, pH 7.5, 10% glycerol, 5 mm EDTA, 5 mm EGTA, 100 mm NaCl, 100 mm Na pyrophosphate, 50 mm NaF, 0.1 mm NaVO 4 , 1% Triton X-100, 1 mm benzamidine, 1 mm phenylmethylsulfonylfluoride, 10 g/ml leupeptin, 10 g/ml aprotinin, 2 g/ml pepstatin) and separated, under denaturing conditions, by SDS-PAGE on 10 -20% gradient polyacrylamide Trisglycine gels (Novex Corp., San Diego, CA). After transfer to polyvinylidene difluoride (Immobilon-P; Millipore Corp., Bedford, MA), the membrane was blocked with 5% nonfat dry milk in 0.2% Tween-20 in Tris-buffered saline (T-TBS) for 1 h at room temperature. The membrane was then placed in a 1:2500 dilution of the antiactive MAPK antibody in 5% nonfat dry milk/T-TBS overnight, at 4 C, with mild agitation. Membranes were then washed 4 ϫ 5 min in T-TBS before incubation in a 1:2500 dilution of horseradish peroxidase-conjugated rabbit antimouse IgG diluted in 1% milk/T-TBS. The membranes were then washed again before proceeding to visualization by enhanced chemiluminescence (ECL) (Renaissance; NEN Life Science Products, Boston, MA). Membranes were stripped (Re-blot Western blot Recycling Kit; Chemicon, Temecula, CA) and reblotted with a polyclonal antibody against extracellular-regulated kinase 2 (ERK2) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 1:5000, washed, and incubated in horseradish peroxidase-conjugated goat antirabbit IgG diluted in 1% milk/T-TBS (Santa Cruz Biotechnology, Inc.), followed by enhanced chemiluminescence detection. The resulting film samples were scanned and analyzed with an image analysis program (NIH Image; Scion Corporation, Frederick, MD). Data are presented as a ratio of phospho-ERK2/total ERK2 in the sample, normalized to control.
Western blot for ER␣ and ER␤
A mouse monoclonal antibody (Clone TE111.5D11: Neomarkers, Fremont, CA) was used to detect ER␣ at a final concentration of 1 g/ml and incubated for 2 h at room temperature. A rabbit polyclonal antibody (Upstate Biotechnology, Lake Placid, NY) was used to detect ER␤ at a final concentration of 1 g/ml. Each membrane was exposed to film for 5 min. All other procedures were performed similarly to the Western blot protocol above.
Transient transfections
Rat-2 cells (ϳ5 ϫ 10 5 cells/well) were plated into 6-well plates and transfected with 1.5 g/well tk-ERE-luciferase (kindly provided by Dr.
Peter Burbach, Rudolf Magnus Institute, University of Utrecht) and 1.0 g/well of either human ER␣ or rat ER␤, or the expression vector pcDNA3 using the diethylaminoethyl/Dextran protocol (Promega Corp.), with slight modifications. One microgram of pCH110, a ␤-galactosidase reporter (Amersham Pharmacia Biotech, Uppsala, Sweden), was added to each well to normalize for transfection efficiency. After 24 h in DMEM, cells (ϳ70% confluent) were transfected at 37 C in diethylaminoethyl/Dextran and 50 m chloroquine phosphate (Sigma) in media supplemented with 10% charcoal-stripped calf serum (Sigma), for 4 h. Media was then replaced, and cells were allowed to recover for 24 h before pharmacological manipulation.
Results
Rat-2 fibroblasts were transfected with cDNA clones encoding either human ER␣ or rat ER␤, and stable cell lines were selected for G418 resistance. A series of clonal populations were isolated and screened for estrogen-sensitive MAPK activation. A single G418-resistant clone was then selected for each receptor transfected (ER␣ and ER␤). We first examined the cells for the presence of ER␣ and ER␤, by Western blot. As expected, untransfected Rat-2 cells do not express either ER␣ or ER␤; whereas the appropriate receptor is detected, using an equivalent exposure time, in ER␣-or ER␤-transfected cells (Fig. 1) .
To determine the relative roles of ER␣ and ER␤ in activating MAPK, transfected Rat-2 cells were treated with 10 nm 17␤-E 2 for 15 min and assayed for estrogen-dependent MAPK activation by immunoblotting with an antiactive MAPK antibody that detects only the dual-phosphorylation state of ERK1/2 (Fig. 2, upper bands) . Blots were then stripped and incubated with an anti-ERK2 antibody to control for the total amount of protein in each lane (Fig. 2, lower bands) . Both ER␣ and ER␤ were able to mediate estrogen-sensitive MAPK activation in Rat-2 cells (Fig. 2) . No activation was observed in untransfected Rat-2 cells, demonstrating that MAPK activation is dependent on the transfected receptors. The magnitude of the response (4-to 6-fold) is consistent with that previously observed in primary neuronal cultures (12) . We chose a dose of E 2 that we found to be saturating in this cell type, namely 10 nm, as determined by the dose response profile (Fig. 3) .
We have previously observed a rapid and sustained activation of MAPK in primary neuronal cell cultures in response to E 2 (12) . MAPK activation kinetics have been implicated in cellular differentiation (18) and may play a role in other cellular processes. To determine the kinetics of MAPK activation, transfected Rat-2 cells were treated with E 2 , and extracts were prepared at various time points (Fig. 4) . MAPK activation by ER␣ peaked at 15 min but returned to nearcontrol levels by 30 min. ER␤ activation of MAPK displayed slightly different kinetics, reaching a maximum near 15 min, with substantial activation still detectable after 1 h. Both ER␣-and ER␤-transfected cells displayed a 4-to 6-fold increase in MAPK activation when treated with E 2 . Distinct pharmacological profiles of antiestrogens or selective estrogen receptor modulators (SERMs) have been shown at both AP-1 sites for ER␣ and ER␤ (19) and in complex promoters (20) . To compare the effects of various SERMs, we next examined their ability to modulate E 2 -mediated MAPK activation (Fig. 5) . Tamoxifen is a partial agonist and is able to reduce E 2 -induced MAPK activation mediated by ER␣. In contrast to the effects seen in Rat-2/ER␣ cells, tamoxifen seems to potentiate ER␤-mediated MAPK activation when combined with E 2 . The dose response profile of tamoxifen-mediated MAPK activation differed significantly between the two receptors (Fig. 6A) . Doses as high as 1 m only weakly activated MAPK in ER␣-transfected cells, whereas ER␤ more robustly increased MAPK phosphorylation in response to this same dose. We also determined the effect of ICI 182,780 on membrane-localized ERs. ICI 182,780 blocks ER␣ but fails to block ER␤-mediated effects, even at doses as high as 1 m (Fig. 6B) . These data suggest that the nuclear ERs are able to function at the cell membrane.
The stereoisomer 17␣-E 2 has been shown to be neuroprotective in SK-N-SH cells (21) , but it only weakly activates transcription. To determine whether 17␣-E 2 is able to activate MAPK, we treated ER␣-and ER␤-transfected cells with in- creasing doses of 17␣-E 2 for 15 min (Fig. 7) . After treatment with 17␣-E 2 , ER-transfected cells displayed increased MAPK phosphorylation, compared with cells treated with vehicle alone.
The observation that BSA-conjugated E 2 , a membrane-impermeable estrogen, activates MAPK in the SK-N-SH neuroblastoma cell line (11) , in addition to earlier reports of BSA-E 2 binding sites at the membrane (22) , has lead to speculation regarding the existence of a novel, membrane-associated ER (23, 24) . To determine whether the transfected receptors were associated with the cell membrane, we treated transfected Rat-2 cells with BSA-E 2 . BSA-E 2 activates MAPK in Rat-2 cells expressing either ER␣ or ER␤ (Fig. 8A) , at a dose similar to that of E 2 treatment alone (10 nm). Similarly to free estrogen, this increase in MAPK phosphorylation is blocked by ICI 182,780 in ER␣-transfected cells but not in those stably expressing ER␤.
Recent reports have shown that many commercially available BSA-conjugated E 2 preparations contain significant quantities of free estrogen. This could potentially explain the inconsistency in the observed responses previously attributed to BSA-E 2 treatment alone. We therefore removed free estrogen that may have been present in our BSA-E 2 preparation by using a method of centrifugation through a 3-kDa cut-off filter cartridge, which has previously been shown to effectively exclude unconjugated hormone (25) . The resulting retentate, containing purified BSA-E 2 , was applied to cells at a final concentration of 10 nm. At this concentration, an equimolar concentration of purified BSA-E 2 was able to elicit an increase in MAPK activation similar to that observed with free estrogen (Fig. 8B) . To confirm the absence of free E 2 in our filtered BSA-E 2 , we examined its ability to activate ERE-mediated transcription using an ERE-luciferase reporter assay in transiently transfected Rat-2 cells (Fig. 9 ). In accordance with our previous observations in SK-N-SH cells (11), BSA-conjugated E 2 was unable to activate an ERE reporter construct. Thus, if there is any unbound estrogen in this filtered BSA-E 2 preparation, the concentration of free estrogen is insufficient to activate nuclear receptor mediated transcription.
The ability of 17␣-E 2 to weakly activate ER-mediated transcription at EREs has been demonstrated in some cell types. Because 17␣-E 2 was able to activate MAPK for both ER␣-and ER␤-expressing Rat-2 cells, we measured its transcriptional activity in transiently transfected Rat-2 cells (Fig. 9) . In these cells, 17␣-E 2 weakly activated ERE-mediated transcription, compared with 17␤-E 2 . The transcriptional activity of both 17␣-E 2 and 17␤-E 2 was blocked by ICI 182,780.
Discussion
Estrogen has been shown to elicit a variety of cellular responses, which can be broadly grouped into transcriptional (or genomic) effects and nontranscriptional (or rapid) effects. One of the more recently described rapid effects of estrogen is activation of the MAPK signal transduction pathway (10) . This activation may be important in many physiological effects of estrogen, which cannot be explained by a transcriptional hypothesis. MAPK activation by E 2 has now been reported in a variety of cell types, including MCF-7 and Caco-2 breast cancer cells, CHO cells, cortical explants, and primary cortical neurons. MAPK activation by ERs has also been implicated in estrogen-mediated neuroprotection (12) and cell cycle regulation (26) .
The mechanism by which the ERs mediate the rapid cytoplasmic effects of estrogen is not well understood. E 2 can elicit a rapid and sustained activation of MAPK in various cells that seems to be mediated by the nonreceptor tyrosine kinase, src (10, 12) . In addition to src, a number of nonreceptor tyrosine kinases of the src family might be involved in mediating MAPK activation. The ER has also been shown to interact with B-raf and heat shock protein 90 (27) , suggesting the possibility of an ER-containing complex involving multiple intracellular proteins.
ER␣ and ER␤ are differentially expressed in a variety of tissues. High levels of ER␣ are found in pituitary, kidney, epididymis, and adrenal; whereas ER␤ is found in prostate, lung, and bladder. Expression of both subtypes overlaps in the brain, ovary, testis, and uterus (28) . Much of the work that has been done on MAPK activation by ERs has been observed in tissues containing both ER␣ and ER␤. In addition, ER␣ and ER␤ can heterodimerize in vitro (29) , thus complicating an analysis of the molecular mechanisms of estrogen action. To examine each receptor individually, we have stably trans- Commercially available BSA-E 2 was purified by centrifugation through a Micron filter cartridge with a 3-kDa cut-off. Cells were treated with vehicle, 10 nM 17␤-E 2 , or 10 nM filtered BSA-E 2 for 15 min and analyzed for MAPK activation as described. Western blot shown is representative of the average Ϯ SEM of three experiments performed in triplicate.
fected Rat-2 cells, which lack ERs, with cDNA clones encoding either ER␣ or ER␤. We found that transfection of either receptor is sufficient to impart estrogen-sensitivity for MAPK phosphorylation. Though the dual phosphorylation of MAPK has been shown to be essential for MAPK activity, we did not directly measure this in the present study. The magnitude of MAPK activation did not differ significantly between the two receptors.
The temporal aspects of activation of MAPK differed between ER␣ and ER␤. ER␣ displayed maximal MAPK activation at 15 min, but this activation dropped to control levels shortly thereafter. ER␤-transfected cells also reached a peak at 15 min, but significant activation was still detectable for at least 1 h after estrogen treatment. Though the kinetics of the two receptors seem to differ slightly, this is in accordance with our earlier observations in primary cortical neuronal cultures, where maximal MAPK activation is seen near 30 min and is sustained for at least 1 h. Furthermore, the duration and timing of MAPK activity have been recently reported as being important to NGF-induced cellular differentiation (18) . The rapid and sustained activation of MAPK by ER␤ is similar to the kinetics observed in primary neuronal cultures (12) , a finding that is consistent with ER␤ being the predominant ER in the adult cortex (30) . Perhaps this sustained pattern of MAPK activation by ER␤ could be important in determining how estrogen will influence cellular function and/or differentiation.
The molecular mechanisms of action of many antiestrogens, such as tamoxifen and ICI 182,780, are not completely understood. Tamoxifen is used clinically in the treatment of breast cancer and is presumed to exert its therapeutic benefits by acting as an ER antagonist. It has been demonstrated in vivo that tamoxifen functions as an agonist of ER␤-mediated effects at AP-1 elements (19) . Because estrogen would be expected to reduce tamoxifen's effects on ER␤ AP-1-mediated gene transcription, the pharmacology of tamoxifen's effects on MAPK activation might play a role in this mode of transcription. Our results show that, with respect to MAPK activation, tamoxifen seems to function as an agonist for ER␤, even slightly potentiating ER␤-mediated effects of E 2 . Tamoxifen does not seem to be an agonist for ER␣-mediated MAPK phosphorylation.
The antiestrogen ICI 182,780 and the other ICI compounds were once thought to be pure antagonists of estrogen action for both ER␣ and ER␤. ICI 182,780 is thought to inhibit receptor dimerization (31) and decrease the half-life of the ER proteins. More recent evidence suggests that the ICI compounds, like tamoxifen, can behave as agonists of ER␤-mediated AP-1 gene transcription (1, 19) . We have found that whereas ICI is able to antagonize E 2 -induced MAPK activation by ER␣, ER␤ is relatively insensitive to this same compound. This result is consistent with observations in primary cortical explants (27) , which express predominantly ER␤ in the adult brain (30) .
We also treated transfected Rat-2 cells with 17␣-E 2 , a stereoisomer of E 2 that has been shown to be neuroprotective in SK-N-SH cells (21) . We found that 17␣-E 2 was able to activate MAPK in a manner similar to that of 17␤-E 2 for both ER␣ and ER␤. 17␣-E 2 has approximately one third of the binding affinity of E 2 for ER␣. It is also a weak agonist for ER␤ at ERE sites (32) . In our cells, 17␣-E 2 can weakly activate ER-mediated transcription at ERE elements, and this activation is susceptible to blockade by ICI 182,780. It is possible that membrane-associated ERs might display similar affinities for both 17␣-E 2 and 17␤-E 2 . The neuroprotective actions of 17␣-E 2 are not thought to be transcriptional in nature (21) . However, its ability to activate MAPK might contribute to this protection in certain cell types.
There has been considerable speculation on the existence of a novel, membrane-associated ER. Previous results from our laboratory have shown that MAPK activation in SK-N-SH cells can occur after treatment with the membraneimpermeable estrogen, BSA-E 2 (11). When we treated transfected Rat-2 cells with BSA-E 2 , we were able to show an increase in MAPK activation similar to that with E 2 treatment for both ER␣ and ER␤. This is in addition to the activation we previously observed with E 2 alone. BSA-E 2 is unable to activate ERE-mediated transcription, thereby demonstrating the membrane-specific nature of this compound. Thus, our results agree with those of Razandi et al. (14) , who reported that introduction of ER␣ into cultured cells imparts sensitivity to the membrane-based actions of estrogen.
There has also been recent interest in the ability of ICI 182,780 to modulate membrane-based ERs differently than for the nuclear population of receptors. Here, ICI might be acting to potentiate membrane-initiated events. It has been demonstrated that ICI 182,780 elicits an increase in cAMP production (4) , an effect that also occurs after BSA-E 2 treatment (33) . We found that ICI blocks BSA-E 2 -induced MAPK signaling in ER␣-, but not ER␤-, transfected cells. This phar- macological pattern is identical for both BSA-E 2 and free estrogen treatment.
It has recently been demonstrated that many commercially available BSA-E 2 preparations contain substantial quantities of free, unconjugated E 2 . Purification of the BSA conjugate, using a method previously documented to eliminate free estrogen (25) , did not alter its ability to activate MAPK. Though it is apparent that BSA-E 2 is not the ideal reagent for studies of membrane-based ERs, our results demonstrate that it is able to activate rapid signaling pathways similarly to that of free estrogen. Furthermore, BSA-E 2 treatment of ER␣-transfected cells was blocked by ICI 182,780, whereas ER␤-transfected cells remained insensitive to ICI blockade.
The downstream targets of estrogen-mediated MAPK activation are just beginning to be explored. This effect on cell signaling is likely to interact with other rapid actions of estrogen, such as PKA activation, as well as coupling to the classical genomic effects of the hormone. MAPK has been shown to directly phosphorylate the ER (34), which modulates its transcriptional activity. Phosphorylation of the receptor via src is also involved in regulating receptor dimerization and transcription at ERE elements. MAPK activation may also contribute to the ability of E 2 to increase CREB phosphorylation (9) , thus enhancing cAMP response element-mediated gene transcription. In summary, ER␣ and ER␤ are sufficient to mediate estrogen-dependent MAPK activation. The effect examined here is too rapid to evoke gene transcription as a possible mechanism of MAPK activation. The unique pharmacology of ER␣ and ER␤ for rapid signaling of this type presents an intriguing new molecular target for future drug development.
